“Treatment-resistant” describes a treatment history. After a failed trial, ask what kind of failure it was
STUDY: Macaluso M, J Psychiatr Pract 2026
STUDY TYPE: Review
FUNDING: Independent
Background
Two failed antidepressant trials earn the label of treatment-resistant depression (TRD). Nearly every one of those drugs works on serotonin, norepinephrine, or dopamine. The TRD label tells you what didn’t work and says little about what’s wrong.
This narrative review proposes a new framework.
Summary
First, check for pseudo-resistance; incomplete trials and incorrect diagnosis:
- Trials that were too short or too low (aim for at least 6 weeks at a therapeutic dose)
- Hidden nonadherence, often after sexual side effects or weight gain
- Rapid metabolism, enzyme inducers, or heavy smoking lowering drug levels
- Missed bipolar II, mixed features, or psychotic depression
- Medical drivers such as hypothyroidism, sleep apnea, low B12, or steroids
Among true nonresponders, the author describes five overlapping groups:
- Still responsive to monaminergic antidepressants. Signs of hope with traditional antidepressants include a past full response, partial current response, or stops due to side effects. Try an atypical antipsychotic, bupropion, lithium, T3, a tricyclic, or an MAOI.
- Monoamine-resistant. Several distinct strategies have failed involving serotonin, norepinephrine, or dopamine. Stop trying similar drugs and move sooner to ketamine, ECT, or other brain stimulation.
- Glutamate-responsive. Ketamines are the standard here (Dr. Aiken’s note: dextromethorphan and amantadine also fit here). We don’t know who is more likely to respond to ketamine, but rapid improvement within the first few ketamine or esketamine doses identifies these patients. Psychotic depression is not a good candidate for these.
- Inflammatory or metabolic. Look for fatigue, oversleeping, overeating, and obesity. In trials, patients with higher hs-CRP did better on nortriptyline or added bupropion than on escitalopram alone. Anti-inflammatory drugs helped a little (effect size 0.35), but only in patients with high hs-CRP (Dr. Aiken’s note: methylfolate, high-dose omega3, and possibly pramipexole are also evidence-based options, as are CBT-insomnia, Mediterranean diet, and exercise).
- Circuit-level. Prominent rumination, poor cognitive control, or anhedonia point toward ECT, TMS, or vagus nerve stimulation. Connectivity-guided accelerated TMS produced remission in 79% versus 13% on sham in a small trial.
Caveat: This is based on the author’s experience and trends in the literature, not on independent validation. The review does not address psychotherapy, which is critical to recovery for all five types.
Practice Implications
- I agree, and describe a similar breakdown in Difficult to Treat Depression, adding vascular and psychotic depression to the list, as well as trauma-related. For the next edition I’ll consider a circadian subtype, pointing toward light therapy. What subtypes would you add?
- Before calling depression resistant, document each prior trial’s dose, duration, and reason for stopping on a structured form such as the Antidepressant Treatment History Form.
- Ask directly about missed doses and hypomania (combine the Bipolarity Index with a screening instrument for manic symptoms, including family input).
- Order a high-sensitivity CRP, hgbA1c, lipids, TSH, LFT, Chem 10 (fasting), CBC, Ferritin, Folate, B12, Vitamin D (25-hydroxy), and check menstrual status, waist measurement, and screen for sleep apnea. For at-risk groups, check lyme, RPR, HIV-1/2 antigen/antibody, syphilis (treponemal test, refer for CSF if reactive), testosterone, urine drug screen
- Track a depression scale (like PHQ-9) at every visit – in one randomized study this measurement-based approach more than doubled remission rates.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report







